Literature DB >> 6361130

Differential recovery of circulating T cell subsets after nodal irradiation for Hodgkin's disease.

G S Haas, E Halperin, D Doseretz, R Linggood, P S Russell, R Colvin, L Barrett, A B Cosimi.   

Abstract

To better understand the immunologic effects of lymphoid irradiation (LI), blood levels of T cell subsets were sequentially monitored in 15 patients before, during, and after irradiation treatment for Hodgkin's disease. Blood levels of all lymphocytes, T cells, and T cell subsets (defined by OKT4 and OKT8) fell dramatically and in similar proportions during early therapy, reaching levels less than 20 to 25% of control by the completion of mantle irradiation, and continuing at very depressed levels through the completion of therapy. Blood levels of OKT8-reactive (OKT8+) cells returned to pretreatment levels (402 +/- 38/mm3 vs 360 +/- 32/mm3 pretreatment) between 6 to 8 mo after LI, whereas blood levels of OKT4-reactive (OKT4+) cells returned to only 42% of previous values (242 +/- 22/mm3 vs 584 +/- 34/mm3 pretreatment) over the same period. The pre-LI ratio of OKT4+ to OKT8+ cells was 1.85 +/- 0.24 and fell to 0.65 +/- 0.05 between 6 to 8 mo after LI. During the recovery period, discrepancies of 208 +/- 32 cells/mm3 (3 to 5 months post LI) and 198 +/- 32 cells/mm3 (6 to 8 mo post LI) developed between the blood levels of OKT3+ cells and the sum of OKT4+ and OKT8+ cells. This suggests the emergence of OKT4+/OKT3-, OKT8+/OKT3-, and/or OKT4+/OKT8+ cells. In five patients, the sum of OKT4+ and OKT8+ cells was compared with the number of cells simultaneously co-stained by OKT4 and OKT8. It appeared that a significant proportion of the cells were OKT4+/OKT3- and OKT8+/OKT3- lymphocytes. We concluded that LI is similarly cytotoxic to peripheral blood T cell subpopulations. The reversed ratio after LI is a result of a slower repopulation of the peripheral blood by OKT4+ cells relative to OKT8+ cells. T cells after LI show a high degree of antigenic immaturity. It is postulated that the bone marrow that lies outside the fields of treatment and contains predominantly immature OKT8+/OKT3- cells is a major source of T cells repopulating the peripheral blood after LI.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361130

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts.

Authors:  A B Farris; D Taheri; T Kawai; L Fazlollahi; W Wong; N Tolkoff-Rubin; T R Spitzer; A J Iafrate; F I Preffer; S A Locascio; B Sprangers; S Saidman; R N Smith; A B Cosimi; M Sykes; D H Sachs; R B Colvin
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

2.  A mature thymocyte-like phenotypic pattern on human cord circulating T-lymphoid cells.

Authors:  R Gerli; P Rambotti; C Cernetti; A Velardi; F Spinozzi; A Tabilio; M F Martelli; F Grignani; S Davis
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

Review 3.  Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?

Authors:  Nadine Housri; Robert Yarchoan; Aradhana Kaushal
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

4.  Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era.

Authors:  Keri L Calkins; Geetanjali Chander; Corinne E Joshu; Kala Visvanathan; Anthony T Fojo; Catherine R Lesko; Richard D Moore; Bryan Lau
Journal:  JAMA Oncol       Date:  2020-02-01       Impact factor: 31.777

5.  Blood lymphocyte subsets after the first fraction in patients given hyperfractionated total body irradiation for bone marrow transplantation.

Authors:  T Girinsky; G Socie; J M Cosset; E P Malaise
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

6.  A machine learning model for grade 4 lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer.

Authors:  Zhiyuan Xu; Li Yang; Hao Yu; Linlang Guo
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.